Literature DB >> 14717120

Genetic and biological properties of HIV type 1 isolates prevalent in villagers of the Cameroon equatorial rain forests and grass fields: further evidence of broad HIV type 1 genetic diversity.

Ping Zhong1, Sherri BUrda, Frank Konings, Mateusz Urbanski, Liying Ma, Leopold Zekeng, Leonard Ewane, Lucy Agyingi, Moise Agwara, Ze E Afane, Thompson Kinge, Susan Zolla-Pazner, Phillipe Nyambi.   

Abstract

To understand the evolution of HIV-1, the genetic and biological characteristics of viruses that infect persons living in regions in which the virus has been evolving for several decades must be studied. Thus, we investigated teh genetic subtypes, coreceptor usage, and syncytium-inducing ability of viruses in 47 HIV-1-infected blood samples from individuals living in rural villages in the equatorial rain forest and grass field regions in Cameroon. Heteroduplex mobility analysis (HMA) of gag (part of p24 and p7) and env (C2V5) or sequence and phylogenetic analysis of gag (part of p24 and p7), pol (protease), and env (C2V5), revealed a broad HIV-1 group M genetic diversity. Subtype analysis revealed genetic evidence of seven subtypes (A, C, D, F, G, H, and J) and three circulating recombinant froms (CRFs) (CRF01_AE, CRF02_AG, and CRF11_cpx). Only 15 (32%) of the 47 samples analyzed revealed a concordant subtype in all three genes (gag, pol, and env), while discordant subtypes and CRFs were identified for the remaining 32 (68%) samples. Two patterns of HIV-1 diversity could be discerned in two provinces. While more concordant subtypes in gag, pol, and env genes were identified in villages of South province (10 of 13, 77%), the HIV-1 diversity in the West province was characterized by intersubtype recombinants (63%). Five new intersubtype recombinants were identified including Agag Jpol Genv, Ggag Upol Aenv, AGgag Jpol Aenv, Agag AGpol Henv, and Cgag AGpol AGenv. All of the 40 viruses tested used the R5 coreceptor, of which four also used the X4 coreceptor. Four viruses were able to induce syncytia in MT-2 cells, however, syncytium induction did not correlate with coreceptor usage. This study further reveals the complexity of HIV-1 infection in rural Cameron and points to the future of the global epidemic, which may be characterized by more genetically diverse viruses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14717120     DOI: 10.1089/088922203771881284

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  17 in total

1.  Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Xiao-Hong Wang; Sherri Burda; Tetsuya Kimura; Frank A J Konings; Arthur Nádas; Christopher A Anyangwe; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Authors:  Chavdar Krachmarov; Abraham Pinter; William J Honnen; Miroslaw K Gorny; Phillipe N Nyambi; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Phylogenetic analysis of the p24-p7 region of the human immunodeficiency virus type 1 gag gene to determine subtype distribution among female sex workers in Calcutta, India.

Authors:  Satarupa Sengupta; Smarajit Jana; Pratim Roy; Kamalesh Sarkar; Sujit K Bhattacharya; Sekhar Chakrabarti
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

4.  Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.

Authors:  Bruce K Brown; Janice M Darden; Sodsai Tovanabutra; Tamara Oblander; Julie Frost; Eric Sanders-Buell; Mark S de Souza; Deborah L Birx; Francine E McCutchan; Victoria R Polonis
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Authors:  Miroslaw K Gorny; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Kathy Revesz; Bradley Witover; Sherri Burda; Mateusz Urbanski; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner; Arthur Nadas
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

6.  High systemic levels of interleukin-10, interleukin-22 and C-reactive protein in Indian patients are associated with low in vitro replication of HIV-1 subtype C viruses.

Authors:  Juan F Arias; Reiko Nishihara; Manju Bala; Kazuyoshi Ikuta
Journal:  Retrovirology       Date:  2010-03-09       Impact factor: 4.602

7.  The Evolution of HIV-1 Diversity in Rural Cameroon and its Implications in Vaccine Design and Trials.

Authors:  Rebecca Powell; Denis Barengolts; Luzia Mayr; Phillipe Nyambi
Journal:  Viruses       Date:  2010-02-12       Impact factor: 5.048

8.  A rare null allele potentially encoding a dominant-negative TRIM5alpha protein in Baka pygmies.

Authors:  Judith N Torimiro; Hassan Javanbakht; Felipe Diaz-Griffero; Jonghwa Kim; Jean K Carr; Mary Carrington; Julie Sawitzke; Donald S Burke; Nathan D Wolfe; Michael Dean; Joseph Sodroski
Journal:  Virology       Date:  2009-07-03       Impact factor: 3.616

9.  Appreciating HIV type 1 diversity: subtype differences in Env.

Authors:  Rebecca M Lynch; Tongye Shen; S Gnanakaran; Cynthia A Derdeyn
Journal:  AIDS Res Hum Retroviruses       Date:  2009-03       Impact factor: 2.205

10.  A heteroduplex assay for the rapid detection of dual Human Immunodeficiency Virus Type 1 infections.

Authors:  Rebecca L R Powell; Mateusz M Urbanski; Phillipe N Nyambi
Journal:  J Virol Methods       Date:  2008-03-07       Impact factor: 2.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.